Biodexa Forum: Community User: Robo1976

CARDIFF, United Kingdom, February 7, 2024 (GLOBE NEWSWIRE) -- Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”)(Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs including Type 1 diabetes (“T1D”) and rare/orphan brain cancers, today announced that the U.S. Patent and Trademark Office allowed U.S. patent application No. 16/546,595 titled “Prevention of Pancreatic Cell Degeneration” which was exclusively licensed to Biodexa by Melior Pharmaceuticals, Inc., along with other patents, in a transaction which closed in December 2023. Stephen Stamp, CEO and CFO of Biodexa, commented “This soon-to-be-issued patent is expected to provide market exclusivity for tolimidone in the U.S. and underpins our investment thesis in ongoing preclinical studies and an upcoming Phase 2 program in Type 1 diabetes patients which we expect to start in next quarter.”

Biodexa Announces Allowance of U.S. Patent Covering Tolimidone February 07, 2024 at 08:30

….

Katalysatoren ausstehend (v.a. erstes Quarta, VP technisch interessant): https://www.stocktitan.net/news/BDRX/biodexa-ceo-issues-shareholder-letter-highlighting-progress-in-2023-smskqndw70fl.html

👌

😄😄😄😄Rakete

Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes November 27, 2023 at 09:01 am EST

@abeni

….

Heute geht es up!

☺️

Wo handelt ihr die Aktie?

🤩🥂🍾

📌

👀

…..